

July 3, 2002

THE CLEVELAND CLINIC  
FOUNDATION 

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane - Room 1061  
Rockville MD 20652

**Ellen S. Rome, M.D., M.P.H.**  
Head, Section of Adolescent Medicine  
Division of Pediatrics / A120  
Office: 216/444-3566  
Appointments: 216/444-5437  
Fax: 216/445-3523

Docket Number: 02N-0152

To Whom It May Concern:

As health care providers and professionals who are committed to improving the physical and psychosocial health and well being of adolescents, the Society for Adolescent Medicine (SAM) welcomes the opportunity to comment on the relationship between the 1998 Pediatric Rule and the Best Pharmaceuticals for Children Act (P.L. 107-109).

SAM is working closely with the American Academy of Pediatrics (AAP) and other pediatric medical and research organizations to ensure that medications are appropriately tested and labeled for infants, children and adolescents. While securing safe and appropriate drugs for use by children and adolescents has had a long and laborious history, significant progress has been made during the last five years toward this goal.

A dual approach to obtaining essential pediatric data was instituted in the late 1990s. This approach combines: 1) incentives for voluntary studies of drug safety and dosing by the pharmaceutical industry (extended in January 2002 in the Best Pharmaceuticals for Children Act [BPCA]); and 2) a regulation requiring pediatric studies of new drugs and some already marketed drugs, known as the Pediatric Rule.

In March 2002, the FDA proposed to suspend the Pediatric Rule. While this proposal was reversed, this action indicates that children and adolescents are at risk of losing the ground we have fought so hard to secure for them.

The Pediatric Rule ensures that children and adolescents are no longer a therapeutic afterthought by the pharmaceutical industry. It is an essential and successful tool in ensuring that children and adolescents have the quality and quantity of drugs they need. All new drugs must be studied for pediatric use at the time a drug comes to market unless the FDA grants a waiver. This makes medications for children and adolescents a certainty, not an option and puts children and adolescents on a level playing field with adults for the first time.

I believe that all components of the 1998 Pediatric Rule must be preserved. It is a comprehensive approach to securing pediatric studies. FDA has not yet invoked all the provisions of the Pediatric Rule; however, together they weave a safety net for children and adolescents to ensure that appropriate drugs are available for their use.

02N-0152

C 20

The following comments and recommendations respond to questions and issues raised in the Federal Register notice soliciting public comments:

Retiring or relaxing any authorities currently in the Pediatric Rule is inappropriate and would be to the detriment of children and adolescents. It must always be kept in mind that BPCA is time-limited, voluntary and subject to continuation by the Congress. Those facts speak directly to the need to ensure that the Pediatric Rule remains in place in its entirety.

Noting again that the BPCA is subject to continuation by Congress and that future reauthorization is uncertain, the Pediatric Rule should mirror the scope of the BPCA and apply to all labeled and potential indications as well as new indications. If a company submits a supplemental indication to the FDA, it invokes the Pediatric Rule. It is important that appropriate pediatric studies be conducted for that new use; and if the current label lacks appropriate pediatric use information, the FDA should also include in their requirement for pediatric studies of the new indication, any pediatric studies that may be needed for the currently labeled or potential indications.

In determining the process of when pediatric studies are conducted, the FDA should rely on the detailed process for requesting pediatric studies of already marketed drugs and securing labeling that is outlined in the BPCA.


It is essential that the Pediatric Rule remain in place because it is the only mechanism that ensures that biological products will be studied and available for children and adolescents. No provision of BPCA applies specifically to biological products since the legislation focuses on drugs covered by the Food, Drug and Cosmetic Act (FDCA) and the vast majority of biologics are covered under the Public Health Service Act. Moreover, some of the most innovative new therapies now and in the future are biological products, which are not covered under BPCA.

Appropriate formulations are an essential component of providing medications for the pediatric population. Failure to require needed formulations for specific age populations negates the intent of the BPCA and the Pediatric Rule.

BPCA limits its reference to "recommendation" for formulation changes only to studies completed under public contract. This provision was included to acknowledge that once a formulation is developed in the study phase, while it may be necessary to manufacture that formulation, it may not always be possible to scale up the formulation for distribution to the general public.

Thank you for your consideration of these comments.

Sincerely,



Ellen S. Rome, M.D., M.P.H.

The Cleveland Clinic Foundation  
Division of Pediatrics  
9500 Euclid Avenue (A120)  
Cleveland, Ohio 44195



FACSIMILE COVER SHEET

To: FDA - Dockets Mgmt (HFA305) Fax No.: 301/827-6870

From: Dr. Ellen Rome Fax No. 216/445-3523

Date: 7-5-02

Total pages (including this cover page): 3

Comments:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Should you experience difficulties receiving this transmission, please contact:

Evelyn at 216/444-3566